瑞他鲁肽 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
=== Reduction to 17% of programs === On March 10, 2025, U.S. Secretary of State Marco Rubio announced that the Trump administration had concluded its review, and 83% of USAID's programs would be cancelled, involving approximately 5,200 contracts.
==== Summary ==== While clear benefits of using magnetic beads include the increased reaction speed, more gentle sample handling and the potential for automation, the choice of using agarose or magnetic beads based on the binding capacity of the support medium and the cost of the product may depend on the protein of interest and the IP method used. As with all assays, empirical testing is required to determine which method is optimal for a given application.
Polyendocrine metabolic ovarian syndrome (PMOS) is an endocrine disorder characterized by an excess of androgens produced by the ovaries. It is estimated that approximately 90% of women with PMOS demonstrate hypersecretion of these hormones. The cause of this condition is unknown. Speculations include genetic predisposition; however, the gene or genes responsible for this remain unidentified. The condition may have a hereditary basis. Other possible causes include elevated insulin production. Most cases of PMOS involve insulin resistance. It is thought that adipose tissue dysfunction plays a role in the insulin resistance seen in PMOS. Insulin can induce excess testosterone secretion from the ovaries. A complication associated with polyendocrine metabolic ovarian syndrome is high cholesterol, which is treated with statins. In a meta-analysis, atorvastatin was shown to decrease androgen concentrations in people with hyperandrogenism. Elevated insulin leads to lower production of sex hormone binding globulin (SHBG), a regulatory glycoprotein that suppresses the function of androgens. High blood levels of insulin also work in conjunction with ovarian sensitivity to insulin to cause hyperandrogenemia, the primary symptom of PMOS. Obese individuals may be more biologically inclined to PMOS due to markedly higher insulin. This hormonal imbalance can lead to chronic anovulation, in which the ovaries fail to release mature eggs. These cases of ovulatory dysfunction are linked to infertility and menstrual disturbances.
== Legacy and honours == 1952: Prix Femina Vacaresco for Mémoires d'Hadrien (Memoirs of Hadrian) 1958: Prix Renée Vivien for Les charités d'Alcippe (The Alms of Alcippe) 1963: Prix Combat for Sous bénéfice d'inventaire (The Dark Brain of Piranesi) 1968: Prix Femina for L'Œuvre au noir (The Abyss) 1972: Prix Prince Pierre de Monaco for her entire oeuvre 1974: Grand Prix national de la culture for Souvenirs pieux (Dear Departed) 1977: Grand Prix de l'Académie française for her entire oeuvre 1980: elected to the Académie française, the first woman so honored 1983: winner of the Erasmus Prize for contributions to European literature and culture 1987: Fellow of the American Academy of Arts and Sciences 2003: 12 November: Belgium issues a postage stamp (Code 200320B) with the value of 0.59 Euro 2020: Google celebrated her 117th birthday with a Google Doodle
Sources: en.wikipedia.org
In other words, if two people receive the same dose of a given drug based on BSA, the concentration of that drug in the bloodstream of one person may be 10 times higher or lower compared to that of the other person. This variability is typical with many chemotherapy drugs dosed by BSA, and, as shown below, was demonstrated in a study of 14 common chemotherapy drugs.
== Temporal resolution == TRMS is typically implemented to monitor processes that occur on second to millisecond time scale. However, there exist reports from studies in which sub-millisecond resolutions were achieved.
== Pharmacology == CVnCoV is an mRNA vaccine that encodes the full-length, pre-fusion stabilized coronavirus spike protein, and activates the immune system against it. CVnCoV technology does not interact with the human genome. CVnCoV uses unmodified RNA, unlike the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine, which both use nucleoside-modified RNA.
Tempeh originated in Indonesia. According to historical evidence, tempeh was first made in Bayat, Klaten, Central Java, and was commonly consumed around 1700. The invention of tempeh seems to have arisen through the serendipitous introduction to stored soybeans of the fungus, which is crucial in tempeh's fermentation. This fungus grows on teakwood and sea hibiscus leaves, which native Javanese people often used (and still do) as food wrappings. In fact, in traditional tempeh making, an usar (a mycelium-filled leaf) is used, instead of store-bought ragi. The type of soybean first used to make tempeh was the black soybean, which was a native plant. This later changed with the importation of white or yellow soybeans and the rise of the tofu industry on the island. While tempeh has not been prominent far from its region of origin, it was reported to have "suddenly taken off" in the United Kingdom in 2025, with annual sales of one brand increasing by 736% (and another by 128%). In North America, a compound growth rate of 6.1% is expected in the tempeh market from 2024-2030, reaching $1519.8 million by 2030.
Global Navigation Satellite System (GNSS) or satnav system – A system of satellites which allows geographical location on Earth (latitude, longitude, and altitude/elevation) to be determined to high precision (within a few metres) by small portable navigation instruments, by timing the arrival of radio signals from the satellites. These are the most widely used navigation systems today. The main satellite navigation systems are the US Global Positioning System (GPS), Russia's GLONASS, China's BeiDou Navigation Satellite System (BDS) and the European Union's Galileo.
Sources: en.wikipedia.org
pyrimidine dimer A type of molecular lesion caused by photochemical damage to DNA or RNA, whereby exposure to ultraviolet (UV) radiation induces the formation of covalent bonds between pyrimidine bases occupying adjacent positions in the same polynucleotide strand, which in turn may cause local conformational changes in secondary structure and prevent base pairing with the opposite strand. In DNA, the dimerization reaction occurs between neighboring thymine and cytosine residues (T−T, C−C, or T−C); it can also occur between cytosine and uracil residues in double-stranded RNA. Pyrimidine dimers are usually quickly corrected by nucleotide excision repair, but uncorrected lesions can inhibit or arrest polymerase activity during transcription or replication.
== Biography == Sakel was born to a Jewish family on June 6, 1900, in Nadvirna (Nadwórna), in the former Austria-Hungary Empire (now Ukraine), which was part of Poland between the world wars. Sakel studied Medicine at the University of Vienna from 1919 to 1925, specializing in neurology and neuropsychiatry. From 1927 until 1933 Sakel worked in hospitals in Berlin. In 1933 he became a researcher for the University of Vienna's Neuropsychiatric Clinic. In 1936, after receiving an invitation from Frederick Parsons, a commissioner of mental hygiene, he chose to emigrate from Austria to the United States of America. In the USA, he became an attending physician and researcher at the Harlem Valley State Hospital. Dr. Sakel was the developer of insulin shock therapy from 1927 while a young doctor in Vienna, starting to practice it in 1933. It would become used widely for individuals with schizophrenia and other mental patients. He noted that insulin-induced coma and convulsions, due to the low level of glucose attained in the blood (hypoglycemic crisis), had a short-term appearance of changing the mental state of drug addicts and psychotics, sometimes dramatically. He reported that as many as 88% of his patients improved with insulin shock therapy, but most other people reported more mixed results and it was shown eventually that patient selection had been biased and that it didn't really have any specific benefits and had many risks, adverse effects and fatalities. However, his method was used for many years in mental institutions worldwide.
Liakhov, a vigorous, able, and reactionary officer firmly committed to upholding absolute monarchies whatever in Russia or Iran, transformed the Persian Cossack Brigade into a mounted para-military police force rather than as a combat force. Liakhov was close to the new Shah, Mohammed Ali, who ascended to the Peacock Throne in January 1907, and it was due to the shah's patronage that Liakhov transformed the Persian Cossack Brigade into the main bulwark of the Iranian state. In June 1908, Liakhov led the Cossack Brigade in bombarding the Majlis (Parliament) while being appointed military governor of Tehran as the shah attempted to do away with the constitution his father had been forced to grant in 1906 Reza Khan, who became the first Iranian to command the Cossack Brigade led the coup d'état in 1921 and in 1925 deposed the Qajars to found a new dynasty. After the outbreak of World War I in August 1914, Cossacks became a key component in the cavalry of the Imperial Russian Army. The mounted Cossacks made up 38 regiments, plus some infantry battalions and 52 horse artillery batteries. Initially, each Russian cavalry division included a regiment of Cossacks in addition to regular units of hussars, lancers, and dragoons. By 1916, the Cossacks' wartime strength had expanded to 160 regiments, plus 176 independent sotnias (squadrons) employed as detached units. The importance of cavalry in the frontlines faded after the opening phase of the war settled into a stalemate.
The deposition of carbonate, leading to a mineralized shell, appears to be related to the acidity of the organic shell matrix (see Mollusc shell); shell-forming cephalopods have an acidic matrix, whereas the gladius of squid has a basic matrix. The basic arrangement of the cephalopod outer wall is: an outer (spherulitic) prismatic layer, a laminar (nacreous) layer and an inner prismatic layer. The thickness of every layer depends on the taxa. In modern cephalopods, the Ca carbonate is aragonite. As for other mollusc shells or coral skeletons, the smallest visible units are irregular rounded granules.
Kardashev first outlined his scale in a paper presented at the 1964 conference that communicated findings on BS-29-76, the Byurakan Conference in the Armenian SSR, which reviewed the Soviet radio astronomy space listening program. The paper was titled "Передача информации внеземными цивилизациями" or Transmission of Information by Extraterrestrial Civilizations. The paper was published in 1964 first in Russian in the March–April issue of the Astronomicheskii Zhurnal, then in English in the September–October 1964 issue of the Soviet Astronomical Journal. In it, the scientist presents a calculation of the evolution of the power needs of humanity. Assuming that overall human power use will continue to increase, he calculates that the rate of energy consumption will cross specific mileposts. Kardashev proposed a typology of technological civilizations based on the evolutive attainment of the three power harnessing mileposts he described. A civilization known as "Type I" has achieved a technological level close to the one attained on Earth at the time Kardashev's article was submitted (December 1963), with a rate of energy consumption evaluated at about 4×1012 watts (W). A civilization known as "Type II" would surpass the first by fourteen orders of magnitude, matching the entire power emitted by the Sun in about 3,200 years, i.e., Earth's home star's "output" at that time, predicted at 4×1026 W.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。